DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Procter & Gamble Hygiene and Health Care Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 1 hr ago·7 Oct 2026, 5:58 am

P&G Hygiene & Health Care

Procter & Gamble Hygiene and Health Care Limited has informed the stock exchanges that it has obtained a certificate of compliance under SEBI's Depositories and Participants Regulations, 2018. This regulatory filing confirms that the company has met all necessary requirements for its securities to continue being listed and traded on the stock market.

For investors, this news is largely procedural and serves as a standard governance check. It confirms that PGHH maintains proper compliance with market regulations, which is essential for the smooth functioning of its shares. This filing does not indicate any operational changes or financial distress, but rather ensures the company remains in good standing with market regulators.

Investors should view this as a routine administrative update. The stock's price action will likely be unaffected unless there are other underlying market factors. Moving forward, market participants should focus on the company's quarterly earnings and product performance rather than this regulatory filing.